IP Library Granted Patent US 11,612,431
Granted Patent B2
US 11,612,431 · App. 16/666,271 · Granted Mar 28, 2023

Methods for monitoring ablation progress with doppler ultrasound

Inventor: Jiayu Chen (Palo Alto, CA)
Assignee: Gynesonics, Inc.
A61B18/1492A61B18/1477A61B90/37A61B2018/00577A61B2018/143A61B2090/378
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,612,431
App. No.
16/666,271
Granted
Mar 28, 2023
Kind
B2
Abstract

Systems and methods for treating tissue are disclosed. The target tissue is ablated. A real-time image of the target tissue is generated during the ablation. The real-time blood perfusion level of the target tissue is determined from the real-time image and compared to an initial blood perfusion level of the target tissue. The comparison provides a metric for the progress of the ablation, and ablation is halted when the real-time blood perfusion drops below a threshold level relative to the initial blood perfusion level.

Claims (28)

1. A method of treating a target tissue, the method comprising:

ablating the target tissue;

monitoring a progress of the ablating of the target tissue by viewing a real-time image of the target tissue to monitor blood perfusion of the target tissue,

wherein the real-time image of the target tissue comprises at least one ultrasound image of the target tissue,

wherein the at least one ultrasound image comprises a B-mode ultrasound image and a Doppler ultrasound image overlaid over one another, and

wherein the B-mode ultrasound image and Doppler ultrasound image overlaid over one another shows blood perfusion of the target tissue; and

overlaying a treatment boundary around the target tissue on the real-time image to guide ablating of the target tissue,

wherein one or more of a size or location of the treatment boundary is located or sized based on the monitored blood perfusion, and

wherein monitoring the progress of ablating of the target tissue further comprises determining a level of Doppler signals within the treatment boundary to provide a completion percentage of the treating of the target tissue.

2. A method as in claim 1 , wherein monitoring the progress of the ablating of the target tissue by viewing the real-time image of the target tissue to monitor blood perfusion of the target tissue comprises determining an initial blood perfusion level of the target tissue within the treatment boundary, determining a real-time blood perfusion level of the target tissue within the treatment boundary, and comparing the initial and real-time blood perfusion levels of the target tissue.

3. A method as in claim 2 , wherein comparing the initial and real-time blood perfusion levels of the target tissue comprises determining whether the real-time blood perfusion level of the target tissue is below the initial blood perfusion level by a threshold amount.

4. A method as in claim 3 , further comprising halting the ablating of the target tissue once the blood perfusion of the target tissue is below the threshold amount.

5. A method as in claim 3 , wherein the threshold amount is 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less of an initial blood perfusion amount of the target tissue.

6. A method as in claim 2 , wherein the initial blood perfusion level comprises an initial Doppler ultrasound signal within the target tissue.

7. A method as in claim 2 , wherein the real-time blood perfusion level comprises a real-time Doppler ultrasound signal within the target tissue.

8. A method as in claim 1 , further comprising fixing a position of an imaging source in relation to the target tissue.

9. A method as in claim 8 , wherein the real-time image of the target tissue is generated during the ablating with the position of the imaging source fixed in relation to the target tissue.

10. A method as in claim 9 , wherein the target tissue is ablated with an ablation element.

11. A method as in claim 10 , wherein the imaging source is fixedly coupled to the ablation element.

12. A method as in claim 10 , wherein the imaging source is removably coupled to the ablation element.

13. A method as in claim 1 , wherein the at least one ultrasound image further comprises a contrast enhanced ultrasound image.

14. A method as in claim 1 , wherein the target tissue is ablated with one or more of RF energy, thermal energy, cryo energy, ultrasound energy, HIFU energy, optical energy, laser energy, X-ray energy, or microwave energy.

15. A method as in claim 1 , wherein ablating the target tissue comprises extending at least one ablation element into the target tissue.

16. A method as in claim 15 , wherein the at least one ablation element comprises one or more of at least one needle or at least one tine.

17. A method as in claim 1 , wherein the target tissue comprises a fibroid, a uterine fibroid, a fibroid tissue, a tumor, a tissue hyperplasia, or an undesired scar tissue.

18. A method as in claim 1 , further comprising introducing a contrast agent into the target tissue prior to the ablation.

19. A method as in claim 1 , further comprising overlaying a safety boundary on the real-time image to guide the ablating of the target tissue.

20. A method as in claim 19 , wherein one or more of a size or location of the safety boundary is located or sized based on the monitored blood perfusion.

Assignments (4)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 070236/0154 Recorded Apr 24, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: GYNESONICS, INC.
Reel/Frame 075455/0789 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Feb 14, 2025
From: GYNESONICS, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 070236/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2019
From: CHEN, JIAYU
To: GYNESONICS, INC.
Reel/Frame 050847/0155 →
Cited By (2)
US 12,239,382 US 12,408,977